A comprehensive pharmacologic-psychosocial treatment program for HIV- seropositive cocaine- and opioid-dependent patients: Preliminary findings

Journal of Substance Abuse Treatment

Volumn 15, Issue 3, 1998, Pages 261-265

  Avants, S Kelly ^a   Margolin, Arthur ^a   Dephilippis, Dominick ^a   Kosten, Thomas R ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Buprenorphine; Bupropion; Cocaine; HIV; Methadone

Indexed keywords

AMFEBUTAMONE; BUPRENORPHINE;

ADULT; ARTICLE; CLINICAL ARTICLE; COMORBIDITY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; OPIATE ADDICTION; PRIORITY JOURNAL; PSYCHOTHERAPY; TREATMENT PLANNING;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BUPRENORPHINE; BUPROPION; COCAINE; DEPRESSION; FEMALE; HIV SEROPOSITIVITY; HUMANS; MALE; METHADONE; MIDDLE AGED; NARCOTIC ANTAGONISTS; NARCOTICS; OPIOID-RELATED DISORDERS; SOCIAL SUPPORT; SUBSTANCE-RELATED DISORDERS;

EID: 0031841709     PISSN: 07405472     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0740-5472(97)00226-2     Document Type: Article

References (27)

1. Arndt I.O., Dorozynsky L., Woody G.E., McLellan A.T. Desipramine treatment of cocaine dependent methadone-maintained patients. Archives of General Psychiatry. 49:1992;888-893.
2. Avants, S.K. (1996). Risk reduction therapy (RRT) for HIV-positive injection drug users. Unpublished treatment manual.
3. Avants, S.K., Margolin, A., McMahon, T., & Kosten, T.R. (1997). Association between self-report of cognitive impairment, HIV status, and cocaine use in a sample of cocaine-dependent methadone-maintained patients. Addictive Behaviors, 22, 599-611.
4. Ball J.C., Ross A. The effectiveness of methadone maintenance treatment. 1991;Springer-Verlag, New York.
5. Batki S.L., Manfredi L.B., Jacob P., Jones R.T. Fluoxetine for cocaine dependence in methadone maintenance. Quantitative plasma and urine cocaine/benzoylecgonine concentrations Journal of Clinical Psychopharmacology. 13(4):1993;243-250.
6. Beck A.T., Ward C.H., Mendelson M., Mock J., Erbaugh J. An inventory for measuring depression. Archives of General Psychiatry. 4:1961;561-571.
7. Camacho L.M., Brown B.S., Simpson D.D. Psychological dysfunction and HIV/AIDS risk behavior. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology. 11:1996;198-202.
8. Dennis M.L., Karuntzos G.T., Rachal J.V. Accessing additional community resources through case management to meet the needs of methadone clients. Ashery R.S. Progress and issues in case management (Vol. 127). 1992;54-78 NIDA Research Monograph Series, Washington, DC.
9. Fernandez F., Ruiz P. Neuropsychiatric complication of HIV infection. Lowinson J., Ruiz P., Millman R. Substance abuse. A comprehensive textbook. 1992;775-787 Williams & Wilkins, Baltimore, MD.
10. Kosten T.R., Morgan C.M., Falcioni J., Schottenfeld R.S. Pharmacotherapy for cocaine-abusing methadone maintained patients using amantadine or desipramine. Archives of General Psychiatry. 49:1992;894-899.
11. Kosten T.R., Oliveto A., Falcioni J., Schottenfeld R.S. Desipramine augmentation of buprenorphine for cocaine abuse. Harris L.S. Problems of drug dependence. 1996;179 NIDA Research, Washington, DC. Monograph Series, Vol. 162
12. Larrat E.P., Zierler S. Entangled epidemics. Cocaine use and HIV disease Journal of Psychoactive Drugs. 25(3):1993;207-220.
13. Lewis J.W. Buprenorphine [Review]. Drug and Alcohol Dependence. 14(3-4):1985;363-372.
14. Majewska M.D. Cocaine addiction as a neurological disorder. Implications for treatment Majewska M.D. Neurotoxicity and neuropathology associated with cocaine abuse (Vol. 163). 1996;1-26 NIDA Research Monograph, Washington, DC.
15. Margolin, A., Avants, S.K., DePhilippis, D., & Kosten, T.R. (in press). A preliminary investigation of lamotrigine for cocaine abuse in HIV-seropositive patients. American Journal of Drug and Alcohol Abuse.
16. Margolin A., Kosten T.R., Avants S.K., Wilkins J., Ling W., Beckson M., Arndt I.O., Cornish J., Ascher J.A., Li S.H., Bridge P. A multicenter trial of bupropion for cocaine dependence in methadone-maintained patients. Drug and Alcohol Dependence. 40:1995;125-131.
17. McKegney F.P., O'Dowd M.A., Feiner C., Selwyn P., Drucker E., Friedland G.H. A prospective comparison of neuropsychologic function in HIV-seropositive and seronegative methadone-maintained patients. AIDS. 4:1990;565-569.
18. McLellan A.T., Arndt I.O., Metzger D.S., Woody G.E., O'Brien C.P. The effects of psychosocial services in substance abuse treatment. Journal of the American Medical Association. 269:1993;1953-1959.
19. Meyer R.E. New pharmacotherapies for cocaine dependence... Revisited. Archives of General Psychiatry. 49:1992;900-904.
20. Mor V., Piette J., Fleishman J.A. Community-based case management for persons with AIDS. Health Affairs. Winter:1989;139-153.
21. National Institutes of Institutes of Health (NIH). (February). Interventions to prevent HIV risk behaviors. Consensus Development Conference, Bethesda, MD, February.
22. Onken L.S., Blaine J.D., Boren J.J. Medications and behavioral therapies. The whole may be greater than the sum of the parts Onken L.S., Blaine J.D., Boren J.J. Integrating behavioral therapies with medications in the treatment of drug dependence. 1995;1-3 NIDA Research Monograph Series, Washington, DC. NIH Publication No. 95-3899 ed., Vol. 150
23. Perry S.W. HIV-related depression. Price R.W., Perry S.W. HIV, AIDS and the brain. 1994;223-238 Raven Press, Ltd, New York.
24. Pocock S.J. The combination of randomized and historical controls in clinical trials. Journal of Chronic Diseases. 29:1976;175-188.
25. Poklis A. Evaluation of Tdx cocaine metabolite assay. Journal of Analytical Toxicology. 11:1987;228-230.
26. Spitzer R.L., Williams J.B.W., Gibbon M. Structured clinical interview for DSM-III-R. 1987;Biometrics Research Department, New York State Psychiatric Institute, New York.
27. Woods S.W., O'Malley S.S., Martini B.L., McDougle C.J., Price L.H., Krystal J.H., Hoffer P.B., Kosten T.R. SPECT regional cerebral blood flow and neuropsychological testing in non-demented HIV-positive drug abusers. Progress in Neuropsycho-Pharmacol Biological Psychiatry. 15:1991;649-662.